Characterization of Rat Cerebral Cortical Beta Adrenoceptor Subtypes Using (-)-[¹²⁵I]-Iodocyanopindolol

References

• Levitzki A., Atlas D., Steer M. L. The binding characteristics and number of beta‐adrenergic receptors on the turkey erythrocyte. Proc. Natl. Acad. Sci. USA 1974; 71: 2772–2776
   Google Scholar
• Nahorski S. R. Association of high affinity stereospecific binding of [3H]‐propranolol to cerebral membranes with beta‐adrenoceptors. Nature 1976; 259: 488–489
   PubMedGoogle Scholar
• Lefkowitz R. J., Mukherjee C., Coverstone M., Caron M. G. Stereospecific [3H](‐)alprenolol binding sites, beta‐adrenergic receptors and adenylate cyclase. Biochem. Biophys. Res. Commun. 1974; 69: 703–710
   Google Scholar
• Aurbach G. D., Fedak S. A., Woodard C. J., Palmer J. S., Hauser D., Troxler T. The beta‐adrenergic receptor: Stereospecific interaction of iodinated beta‐blocking agent with a high affinity state. Science 1974; 186: 1220–1224
   Google Scholar
• Barovsky K., Brooker G. (‐)[125I]‐iodopindolol, a new highly selective radioiodinated β‐adrenergic receptor antagonist: Measurement of β‐receptors on intact rat astrocytoma cell. J. Cyclic Neucleotide Res. 1980; 6: 297–307
   PubMedGoogle Scholar
• Engel G., Hoyer D., Berthold R., Wagner H. (±)‐[125Iodo]‐cyanopindolol, a new ligand for β‐adrenoceptors: Identification and quantitation of subclasses of β‐adrenoceptors in guinea pig. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1981; 317: 277–285
   Google Scholar
• Willcocks A. L., Nahorski S. R. Binding of 125I‐iodohydroxybenzylpindolol to cerebral membranes: Association with 5‐hydroxytryptamine recognition sites as well as beta‐adrenoceptors. Biochem. Pharmacol. 1983; 32: 331–3319
   Google Scholar
• Alexander R. W., Davis J. N., Lefkowitz R. J. Direct identification and characterization of beta‐adrenergic receptors in rat brain. Nature 1975; 258: 437–439
   PubMed Web of Science ®Google Scholar
• Bylund D. B., Snyder S. H. Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 1976; 12: 568–580
   PubMed Web of Science ®Google Scholar
• Sporn J. R., Molinoff P. B. β‐adrenergic receptors in rat brain. J. Cyclic Nucleotide Res. 1976; 2: 146–161
   Google Scholar
• Morin D., Zini R., Brunner F., Sebille B., Tillement J. ‐P. Thermodynamic study of iodocyanopindolol β‐adrenoceptor interactions with rat lung and cerebral cortex. J. Receptor Res. 1983–1984; 3: 773–790
   PubMed Web of Science ®Google Scholar
• Petrovic S. L., McDonald J. K., Snyder G. D., McCann S. M. Characterization of β‐adrenergic receptors in rat brain and pituitary using a new high affinity ligand, [125I]iodocyanopindolol. Brain Res. 1983; 261: 249–259
   PubMed Web of Science ®Google Scholar
• Edwards E., Whitaker‐Azmitia P. M. Selective β‐antagonists are equally and highly potent at 5‐HT sites in the rat hippocampus. Neuropharmacology 1987; 26: 93–96
   PubMedGoogle Scholar
• Hoyer D., Engel G., Kalkman H. O. Characterization of the 5HT1B recognit‐ion site in rat brain: Binding studies with (‐)[125I]iodocyanopindolol. Eur. J. Pharmacol. 1985; 118: 1–12
   PubMedGoogle Scholar
• Hoyer D., Engel G., Kalkman H. O. Molecular pharmacology of 5HT1 and 5HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]5‐HT, [3H]8‐OH‐DPAT,(‐)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserine. Eur. J. Pharmacol. 1985; 118: 13–23
   PubMed Web of Science ®Google Scholar
• Offord S. J., Ordway G. A., Frazer A. Application of [125I]iodocyanopindolol to measure 5‐hydroxytryptamine 1B receptors in the brain of the rat. J. Pharmacol. Exp. Ther. 1988; 244: 144–153
   PubMedGoogle Scholar
• Setchenska M. S., Bonanou‐Tzedaki S. A., Arnstein H. R.B. Classification of β‐adrenergic subtypes in immature rabbit bone marrow erythroblasts. Biochem. Pharmacol. 1986; 35: 3679–3684
   PubMedGoogle Scholar
• Tovey K. C., Oldham K. G., Whelam J. A.M. A simple direct assay for cAMP in plasma and other biological samples using an improved competitive protein binding technique. Clin. Clim. Acta 1974; 56: 221–234
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. T., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• McPherson G. A. KINETIC, EBDA, LIGAND, LOWRY: A Collection of Radioligand Binding Analysis Programs. Elsevier, Amsterdam 1985
   Google Scholar
• Lands A. M., Arnold A., McAuliff J. P., Luduena F. P., Brown T. C. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–598
   PubMed Web of Science ®Google Scholar
• Hancock A. A., Delean A. L., Lefkowitz R. J. Quantative resolution of β‐adrenergic receptor subtypes by selective ligand binding: Application of a computerized model fitting technique. Mol. Pharmacol. 1979; 16: 1–9
   PubMed Web of Science ®Google Scholar
• Neve K. A., McGonigle P., Molinoff P. B. Quantitative analysis of the selectivity of radioligands for subtypes of β‐adrenergic receptors. J. Pharmacol. Exp. Ther. 1986; 238: 46–53
   PubMedGoogle Scholar
• Burgisser E. Model testing in radioligand/receptor interaction by Monte Carlo simulation. J. Receptor Res. 1983; 3: 261–281
   PubMed Web of Science ®Google Scholar
• Ross E. M., Maguire M. E., Sturgill T. W., Biltonen R. L., Gilman A. G. Relationship between the β‐adrenergic receptor and adenylate cyclase. J. Biol. Chem. 1977; 252: 5761–5775
   PubMed Web of Science ®Google Scholar
• Hoyer D., Engel G., Berthold R. Binding characteristics of (+), (±) and (‐)[125I]iodocyanopindolol to guinea pig left ventricle membranes. Naunyn‐Schmiedeberg's Arch. Pharmacol. 1982; 318: 319–329
   Google Scholar
• Keshles O., Levitzki A. The ontogenesis of β‐adrenergic receptors and of adenylate cyclase in the developing rat brain. Biochem. Pharmacol. 1984; 33: 3231–3233
   PubMedGoogle Scholar
• Okada F., Tokumitsu Y., Ui M. Desensitization of β‐adrenergic receptor‐coupled adenylate cyclase in cerebral cortex after in vivo treatment of rats with desipramine. J. Neurochem. 1986; 47: 454–459
   PubMedGoogle Scholar
• Svendsen T. L., Hartling O., Trap‐Jensen J. Immediate hemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI‐89406 in healthy volunteers. Eur. J. Clin. Pharamcol. 1979; 15: 223–228
   PubMed Web of Science ®Google Scholar
• O'Donnell S. R., Wanstall J. C. Evidence that ICI‐118551 is a potent, highly beta2‐selective adrenoceptor antagonist and can be used to characterize beta‐adrenoceptor populations in tissues. Life Sci. 1980; 27: 671–677
   PubMedGoogle Scholar